SCHEMBL14947384

SCHEMBL14947384

CCCCC/C=C\C/C=C\CCCCCCCCCC(CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)N(CC)CCCN(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
HPGD P15428 2/20 0.43
CNR1 P21554 2/20 0.43
FAAH O00519 1/20 0.43
MAPT P10636 1/20 0.43
CNR2 P34972 1/20 0.43
KDM4E B2RXH2 3/20 0.41
F7 P08709 3/20 0.41
F3 P13726 3/20 0.41
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
DUSP3 P51452 1/20 0.41
PTPN7 P35236 1/20 0.41
FFAR1 O14842 1/20 0.41
LMNA P02545 1/20 0.41
FABP3 P05413 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP19A1 P11511 1/20 0.41
FABP4 P15090 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12186607 0.95 ALDH1A1 (0.45) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL14935423 0.95 ALDH1A1 (0.45) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL12186603 0.94 ALDH1A1 (0.44) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL10008598 0.94 ALDH1A1 (0.44) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL10008604 0.94 ALDH1A1 (0.44) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL14935167 0.94 ALDH1A1 (0.44) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL12186770 0.93 ALDH1A1 (0.43) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL12187648 0.91 ALDH1A1 (0.44) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL22391194 0.91 ALDH1A1 (0.42) ALDH1A1HPGDCNR1FAAHMAPT
SCHEMBL2640945 0.91 ALDH1A1 (0.42) ALDH1A1HPGDCNR1FAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865675-B2 Compositions and methods for silencing apolipoprotein B PROTIVA BIOTHERAPEUTICS, INC. (CA) 2014-10-21 US disclosed
US-8865675-B2 Compositions and methods for silencing apolipoprotein B PROTIVA BIOTHERAPEUTICS, INC. (CA) 2014-10-21 US disclosed
US-20130123339-A1 COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B PROTIVA BIOTHERAPEUTICS INC (CA) 2013-05-16 US disclosed
US-20130123339-A1 COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B PROTIVA BIOTHERAPEUTICS INC (CA) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123339-A1 COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B APOB, LDLR, APOL1 ALDH1A1 3439/4885HPGD 4421/4885CNR1 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.